Key Takeaways:
- Lilly's oral GLP-1 pill orforglipron beat Novo Nordisk's oral semaglutide in head-to-head diabetes trials presented at ADA 2024
- Orforglipron delivered superior blood sugar control and weight loss across three Phase 3 trials involving over 6,000 people with type 2 diabetes
- Eli Lilly plans to file for diabetes approval by June 30 using a Commissioner's National Priority Review Voucher, potentially bringing the second FDA-approved indication within months
- Unlike oral semaglutide, orforglipron can be taken any time of day without food or water restrictions
Orforglipron Dominates Head-to-Head Diabetes Showdown
Eli Lilly announced detailed results from three Phase 3 trials in the ACHIEVE program evaluating orforglipron, a small molecule oral GLP-1 taken without food or water restrictions, in adults with type 2 diabetes Source. The results, presented Monday at the American Diabetes Association's 86th Scientific Sessions, show Lilly's oral pill consistently outperforming competitors.
In the landmark head-to-head ACHIEVE-3 trial, orforglipron outperformed oral semaglutide across the primary and all key secondary endpoints Source. This marks the first direct Phase 3 comparison between two oral GLP-1 medications—a showdown between pharmaceutical giants that Lilly decisively won.
The 52-week trial enrolled 1,698 participants across four treatment arms: orforglipron 12 mg and 36 mg, and oral semaglutide 7 mg and 14 mg Source. In ACHIEVE-2 and ACHIEVE-5, orforglipron met the primary endpoint and key secondary endpoints, delivering superior A1C reduction and weight loss versus dapagliflozin and placebo added to insulin glargine respectively Source.
What Makes Orforglipron Different—And Better
Orforglipron isn't another GLP-1 medication. Orforglipron's key differentiator over oral semaglutide is its non-peptide structure, which allows dosing without food or water restrictions — a meaningful convenience advantage over semaglutide's requirement for fasting administration Source.
This matters more than you might think. If you've ever tried oral semaglutide (the pill version of injectable semaglutide), you know the drill: take it first thing in the morning, wait 30-60 minutes before eating or drinking anything, and hope you don't forget and grab that morning coffee. Orforglipron is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake Source.
Orforglipron, a non-peptide small molecule originally discovered by Japan-based Chugai Pharmaceutical and licensed by Lilly in 2018, is already US FDA-approved for chronic weight management under the brand name Founday Source. Now Lilly wants to expand its label to include diabetes treatment.
Racing to FDA With Priority Review
Based on these findings, as well as those from ACHIEVE-1 and ACHIEVE-4, Lilly plans to submit orforglipron for the treatment of type 2 diabetes to the U.S. FDA by the end of the second quarter under the Commissioner's National Priority Review Voucher Source. That's less than three weeks away.
The priority voucher system allows faster FDA review for medications addressing critical national health priorities. The ACHIEVE Phase 3 global clinical development program for orforglipron has enrolled more than 6,000 people with type 2 diabetes across five global registration trials Source, giving Lilly robust data to support their submission.
Pfizer's danuglipron, another oral small-molecule GLP-1 agonist, remains in development but has faced tolerability challenges, leaving orforglipron as the most advanced non-peptide oral GLP-1 candidate in the diabetes space Source.
Side Effects Tell the Real Story
While orforglipron showed superior effectiveness, it came with a trade-off. Treatment discontinuation rates due to adverse events were 8.7% and 9.7% with orforglipron 12 mg and 36 mg vs. 4.5% and 4.9% with oral semaglutide in ACHIEVE-3 Source. This suggests orforglipron may cause more gastrointestinal side effects—the main reason people stop GLP-1 medications.
However, for many people, the convenience factor may outweigh the slightly higher discontinuation rates. No food restrictions means you can take your medication when it works for your schedule, not when your stomach is empty.
The most common side effects reported were nausea, vomiting, and diarrhea—similar to what's seen with other GLP-1 medications. Most side effects were mild to moderate and decreased over time as people's bodies adjusted to the medication.
Market Competition Heats Up
This head-to-head victory positions Lilly to challenge Novo Nordisk's dominance in the oral GLP-1 space. ACHIEVE-3 compared orforglipron head-to-head against Novo's oral semaglutide, marketed as Rybelsus for diabetes Source—though the same compound is also available as Wegovy for weight loss.
Lilly already offers Founday for weight loss at competitive pricing. If you have commercial insurance, you may pay as little as $25 per month with the savings card, while self-pay starts at $149 monthly for the lowest dose—significantly less than most brand-name GLP-1 medications. You can learn more about pricing options in our comprehensive cost guide.
The diabetes market represents a massive opportunity. With over 37 million Americans living with diabetes and many struggling with current treatment options, an oral GLP-1 that's both effective and convenient could reshape diabetes care.
What This Means for You
If you're managing type 2 diabetes and struggling with the food restrictions of oral semaglutide—or if you can't afford the $800+ monthly cost of brand-name options—orforglipron's potential diabetes approval could change your treatment options significantly.
The convenience of any-time dosing combined with Lilly's competitive pricing strategy could make this the most accessible oral GLP-1 option yet. With FDA submission expected by June 30 and priority review status, approval could come within 6-8 months rather than the typical 10-12 month timeline.
If you're currently on diabetes medications that aren't working well enough, or if you're interested in exploring GLP-1 options for both diabetes and weight management, this development is worth discussing with your healthcare provider. Many telehealth providers are already preparing to offer orforglipron for diabetes once approved, which could make access even more convenient.
For those ready to explore current GLP-1 options, you can connect with experienced providers through GLP-1 Clinics who can help determine if these medications are right for your situation.
Sources
- Eli Lilly Press Release - ACHIEVE trial results announced June 8, 2024
- BioSpace Analysis - Head-to-head comparison results
- The Lancet Publication - ACHIEVE-3 detailed results
- AllSci Medical Analysis - Clinical trial comparison